Close Menu

Phadia

The incubator, housed on the campus of the Karolinska Institute, draws upon the experience of its partners in genomics, diagnostics, business development, and corporate law.

Movers & Shakers: Sep 16, 2011

Premium

Olink Bioscience this week appointed Simon Fredriksson as its new president and CEO, replacing Bjorn Ekstrom, who has led the company since its founding in 2004 and will be joining its board of directors.

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today raised its adjusted EPS and revenues guidance for full-year 2011 following the completion of its purchase of specialty diagnostics firm Phadia.

The company has entered a bridge credit agreement for $2 billion and a revolving credit agreement for up to $1 billion.

The acquisition, expected to close in the fourth quarter, will give Thermo Fisher Phadia's immunoassay-based allergy testing and autoimmune disease-testing products.

The acquisition will significantly expand Thermo Fisher's specialty diagnostics business from current annual revenues of around $1.4 billion to roughly $1.9 billion.

The company's Multiplexing Diagnostics division will use the arrayer to develop molecular tools, including protein biomarkers, to diagnose allergy and autoimmunity.

Phadia will use the 2470 in its research efforts to characterize new allergens and to discover biomarker signatures that can be used in the molecular diagnosis of allergies and autoimmune diseases.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.